Journal Article

Clinical Experience with Linezolid for the Treatment of <i>Nocardia</i> Infection

Edina H. Moylett, Susan E. Pacheco, Barbara A. Brown-Elliott, Tracy R. Perry, E. Stephen Buescher, Mary C. Birmingham, Jerome J. Schentag, Joseph F. Gimbel, Aaron Apodaca, Margot A. Schwartz, Robert M. Rakita and Richard J. Wallace

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 3, pages 313-318
Published in print February 2003 | ISSN: 1058-4838
Published online February 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/345907
Clinical Experience with Linezolid for the Treatment of Nocardia Infection

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Linezolid is an oxazolidinone that has activity against most gram-positive bacteria, including in vitro activity against all Nocardia species and strains. We describe 6 clinical cases of nocardiosis that were successfully treated with linezolid. Two patients had underlying X-linked chronic granulomatous disease, and 2 patients were receiving chronic corticosteroid therapy. Four of 6 patients had disseminated disease, and 2 of these 4 patients had multiple brain abscesses. Four patients primarily received monotherapy; for the fifth patient, linezolid was added to a failing multiple-drug regimen, and, for the sixth patient, it was used as part of combination therapy. All 6 patients were successfully treated, although 1 patient had a presumed relapse of central nervous system infection after premature discontinuation of the drug. Linezolid appears to be an effective alternative for the treatment of nocardiosis.

Journal Article.  2848 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.